Private Health Insurance In China: Keeping Up With The Evolving Payor System
The global pharmaceutical industry faces challenges in tapping into China’s booming health care market; coverage under public insurance is still very limited and what patients can afford to spend out-of-pocket is still inadequate for high-cost innovative medicines. Can private health insurance close the gap?
You may also be interested in...
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
The combination of bupivacaine and meloxicam will be priced at a discount to Exparel, with Heron predicting rapid uptake. Label limited to three surgery types, but analysts expect off-label use.
Increasing number of product development meetings suggests that many complex generics remain in the development stages.